POPULARITY
7 episodes with autologous
8 episodes with autologous
5 episodes with autologous
4 episodes with autologous
3 episodes with autologous
3 episodes with autologous
4 episodes with autologous
2 episodes with autologous
2 episodes with autologous
In this week's episode of The Dr. Joy Kong Podcast, I sit down with a fellow expert, the amazing Dr. Scott Martin.Dr. Martin is a pioneer in regenerative medicine who has consulted for multiple biotech companies and advocates for holistic, patient-centered care.Together, he and I will be discussing the common misconceptions in the industry, including whether birth tissue products truly contain live cells, if some professionals in the field are exploiting patients for profit, and why these problems have gone unaddressed for far too long.We will also be talking about:The ethics behind using birth tissue in stem cell treatmentsThe personal attacks I have suffered as a regenerative medicine doctorWhy the future of regenerative medicine lies in patient outcomes, not product sales… and a lot more!Are you ready?Let's dive in.Key Takeaways:Introduction (00:00)Dr. Scott Martin's background and contributions (02:05)Challenges in regenerative medicine (03:37)Regulatory and market challenges (08:11)Autologous vs. Allogeneic biologics (15:50)Manipulation of scientific literature (22:05)Manipulated research methods in autologous biologic studies (37:57)Ethical discussion: providing all options in biologic treatments. (1:10:08)Closing remarks (1:26:30)Additional Resources: ✨ Learn more about how to live a long and pain-free life: https://joykongmd.com/ ✨ Follow me on Facebook: https://www.facebook.com/stemcelldrjoy/ ✨ Follow me on Instagram: https://www.instagram.com/dr_joy_kong/ —Dr. Joy Kong is a regenerative medicine and anti-aging expert. Her podcast is part of her mission to reduce suffering and elevate happiness. Join us every week for the latest holistic health insights that will help you live a long and pain-free life.
Brian Flesner, DVM, MS, DACVIM (Oncology), discusses the recently opened clinical trial studying an Autologous Cancer Vaccine with Checkpoint Inhibitor for the Treatment of Canine Osteosarcoma.The purpose of this study is to evaluate the safety and efficacy of K9-ACV, an autologous killed tumor cell vaccine combined with a novel checkpoint inhibitor (CD200AR-L), compared to standard-of-care chemotherapy for the treatment of canine appendicular osteosarcoma (OSA). K9-ACV has safely been used in over 1,000 dogs, and the vaccine has been shown to display safety in a previous study (without the addition of the checkpoint inhibitor). By evaluating K9-ACV, this trial aims to advance safer, immune-based treatment options for canine cancer that may offer comparable or superior outcomes to chemotherapy.Find more information about this study:https://studypages.com/s/autologous-cancer-vaccine-with-checkpoint-inhibitor-for-treatment-of-canine-osteosarcoma-565406/Adrienne Wright, adrienne@ardentanimalhealth.com, +1 (859) 619-5893
Dr. Justin Abbatemarco provides an update on autologous hematopoietic stem cell transplantation in multiple sclerosis. Show reference: https://www.nature.com/articles/s41582-024-01050-x
Autologous haematopoietic stem cell transplantation (AHSCT) has gained considerable attention in recent years as a treatment option for multiple sclerosis (MS). As long-term clinical trial data on AHSCT continues to grow, there is increasing debate about where it fits in the current MS therapeutic landscape. Dr. Joachim Burman, Neurologist and Associate Professor at Uppsala University in Sweden, and Dr. Jennifer Massey, Neurologist at St. Vincent's Hospital and a Senior Lecturer at the University of New South Wales in Australia, discuss the latest research and insights on this hot topic with host Brett Drummond of MStranslate.
Send us a textIn a world of rapid advancements in medical science and biotechnology, bioprocessing is at the forefront of healthcare innovation. Yet, despite remarkable progress, life-saving biotherapeutics remain out of reach for much of the global population.A staggering 80% of patients worldwide lack access to the biotherapeutics they need. While bioprocessing has made impressive strides, the high cost and slow development of these treatments create significant barriers. Addressing these challenges is critical to making innovative therapies widely available.David Brühlmann is launching a special four-part series based on his keynote at the Amphacademy, exploring bioprocessing's revolutionary journey - from the early days of recombinant insulin to today's groundbreaking therapies. This series will also highlight strategies to make these innovations more accessible to patients worldwide.From Standardization to PersonalizationOne major challenge is the shift away from platform technologies. Traditionally, antibodies were produced using standardized CHO cell templates and purification steps, but this approach falls short for new modalities.Personalized therapies further complicate the landscape. Autologous cell therapies, for example, require isolating, cultivating, and reinfusing a patient's own cells. These small-batch processes are labor-intensive, less automated, and often reliant on outdated, paper-driven workflows.Innovations in Bioreactor DesignWith the rise of sensitive cell therapies, bioreactor design must evolve. Unlike CHO cells, these delicate cells require gentler handling environments. Innovations like acoustic wave bioreactors, bionic bioreactors, and specialized cell screws are emerging to optimize cell growth and improve efficiency.The Complexity and Cost of Cell-Based ProductsNew bioprocessing modalities bring greater complexity. Cell-based therapies and cultivated meats are far more intricate than traditional antibody proteins, making scaling production and ensuring quality especially challenging.High production costs further limit access. Even in regions where these therapies are approved, pricing remains a major barrier. Lowering manufacturing costs is essential to democratizing these life-saving treatments.The shift from basic recombinant proteins to complex cell-based therapeutics is just the beginning. Overcoming these challenges - scaling production, reducing costs, and managing complexity - is key to making breakthrough therapies accessible to all.Next step:Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t
Exploring the Human Microbiome with Dr. Joël Doré: The Future of Gut Health Science In this episode of Inside Matters, Dr James McIlroy engages in an enlightening conversation with Dr. Joël Doré, Research Director at the French National Research Institute for Agriculture, Food and Environment (NRAE). With over 40 years of experience in microbiome research, Dr. Doré shares his extensive knowledge on probiotics, gut health protocols, at-home microbiome testing, and the gut-brain axis. The discussion delves into the intricacies of the human microbiome symbiosis, the evolutionary development of gut microbiota, and its impact on health conditions such as obesity and chronic diseases. Dr. Doré also sheds light on innovative treatments like faecal microbiota transfer and the significance of microbial diversity for a healthy gut. Tune in to discover how the future of medicine and nutrition hinges on understanding and leveraging the microbial human. Takeaways The human body consists of roughly 50 trillion bacteria and 50 trillion human cells. Gut microbiota aids in digestion and protects against harmful bacteria. Microbiota educates the immune system, keeping it ready to react. The microbiome develops from birth, influenced by diet and birth method. C-section births can delay microbiota diversification and increase the risk of chronic conditions. Diversity in the microbiome is crucial for health and chronic disease prevention. At-home microbiome testing lacks standardization and medical utility. Low microbiome richness is linked to higher chronic disease risks. Microbiome diversity can predict responses to obesity treatments. Acrimantium may play a role in health, but microbial ecosystem diversity is crucial. Fecal microbiota transfer can significantly aid cancer treatment. Probiotics may not establish long-term but can still be effective during gut transit. The 100,000 Microbiome Project aims to explore gut health across all ages. Gut permeability issues can lead to neuroinflammation and mental health challenges. Future medicine will focus on the microbial aspects of human health. Chronic conditions are increasingly linked to microbiome health. Dietary choices profoundly impact gut microbiota diversity. Research is ongoing to better understand the gut-brain connection. Preventive nutrition should consider microbial health as a key factor. Timestamps 00:00 Introduction to Dr. Joël Doré and Microbiome Research 00:32 Exploring Probiotics and Gut Health Protocols 00:49 At-Home Microbiome Testing: Strengths and Limitations 01:38 Understanding the Human Microbiome Symbiosis 02:48 The Role of Gut Microbiota in Health and Disease 08:18 Microbiome Development from Birth 11:08 Impact of Birth Methods and Early Life on Microbiome 12:00 Antibiotics and Microbiome Diversity 17:48 Challenges in Defining a Healthy Microbiome 24:38 At-Home Microbiome Testing: Current State and Future Directions 32:51 Microbiome and Obesity: Insights from Research 34:21 Microbiome and Immunotherapy: Potential and Challenges 39:02 Prognostic Model and Microbiota Transfer 40:21 Mad Pharma: Pioneering Fecal Microbiota Transfer 41:50 Autologous and Allogenic Microbiota Transfer 43:53 Challenges and Innovations in Microbiota Transfer 51:25 Probiotics: Do They Work? 01:01:50 The Best Diet for the Microbiome 01:03:00 The 100,000 Microbiome Project 01:08:13 The Gut-Brain Connection 01:12:58 Vision for the Future of Microbiome Research 01:14:35 Conclusion and Final Thoughts
In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Edward I. Chang, MD, discuss the following articles from the February 2025 issue: “Contralateral Autologous Augmentation in DIEP Flap Reconstruction: Employing Computed Tomography Angiography and Volumetric Analysis for Preoperative Planning” by Hespe, Sugg, Stein, et al. Read the article for FREE: https://bit.ly/CTAugPlanning Special guest, Edward I. Chang, MD, who is a board-certified plastic surgeon and Professor in the Department of Plastic Surgery at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Chang trained at the University of California San Francisco for plastic surgery residency, followed by a fellowship in microvascular reconstructive surgery at the University of Texas MD Anderson Cancer Center in Houston, Texas. He was the 2024 ASRM Godina Fellow, currently serves on the editorial board of PRS Journal, and is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCFeb25Collection
Commentary by Dr. Oscar Calvillo-Argüelles.
Send us a textThe MedStar Georgetown University Hospital Stem Cell Transplant and Cellular Immunotherapy Program is the only adult, FACT-accredited program in the Washington, D.C., area. We give patients with cancers affecting the blood or immune system and other disorders access to life-saving treatment options not otherwise available in our region. These include:· Allogeneic stem cell transplant· Autologous stem cell transplant· CAR T-cell therapyAlaa Ali, MD, MSC, is a clinician, instructor, and investigator in clinical and translational research at MedStar Georgetown's Stem Cell Transplant and Cellular Immunotherapy program. Concurrrently, he holds the position of Assistant Professor at Georgetown University School of Medicine.For an interview with Dr. Ali, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net. Learn more about Dr. Ali. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.
Dr. Bobby Cowles talks about recent research on Autologous protein solution (APS) and how could it help horses with Synovitis.Host: Coach JennTodays contributor: Dr. Bobby Cowles, DVM, MS, MBA, Managing Veterinarian, Equine Technical Services, ZoetisLink: Zoetis Equine Lameness solutionsLink: Zoetis Equine ProductsSponsored by MyNewHorse.comSupport for this episode provided by HRN AuditorsListen to more podcasts for horse people at Horse Radio Network
Dr. Bobby Cowles talks about recent research on Autologous protein solution (APS) and how could it help horses with Synovitis.Host: Coach JennTodays contributor: Dr. Bobby Cowles, DVM, MS, MBA, Managing Veterinarian, Equine Technical Services, ZoetisLink: Zoetis Equine Lameness solutionsLink: Zoetis Equine ProductsSponsored by MyNewHorse.comSupport for this episode provided by HRN AuditorsListen to more podcasts for horse people at Horse Radio Network
In this episode of LifeSciences 360, we dive into the fascinating world of cell and gene therapy manufacturing with Carlos Yuraszeck. With over 16 years of experience, Carlos shares his deep insights into the unique challenges, opportunities, and innovations in the field, offering a detailed look into what it takes to bring life-saving therapies to patients. We cover everything from the design of manufacturing facilities to the complexities of quality systems, patient-centric innovations, and the future of allogeneic therapies.If you're interested in the life sciences, cell and gene therapy, or just curious about cutting-edge advancements in medicine, this episode is for you!Chapters:00:00 - Intro 00:02 - Understanding Cell and Gene Therapy Facilities 00:09 - Challenges in Cell Therapy Facility Design 00:26 - Automation in Manufacturing 00:42 - Balancing Quality, Cost, and Time 00:53 - Patient-Centric Manufacturing 01:21 - Guest Introduction: Carlos Yuraszeck 02:06 - Carlos's Journey in Cell and Gene Therapy 03:21 - Unique Factors in Facility Design 04:14 - Making Facilities Operational 05:09 - Subscription Appeal 06:13 - Autologous vs. Allogeneic Cell Therapies Explained 08:13 - Adjusting Processes Based on Patient Variability 09:37 - Stem Cell Derived Therapies 10:39 - Biotech Companies: Autologous or Allogeneic? 12:07 - Strategic Decisions in Facility Design 14:50 - Phase-Appropriate Quality Systems 16:45 - Regulatory Flexibility and Urgency for Patients 18:08 - Change Control in Early vs. Late Phases 19:02 - Batch Records and Operator Judgment 20:27 - Training Focus for Different Phases 22:38 - Balancing Regulatory Requirements and Innovation 24:32 - Risk Assessment Based on Patient Needs 26:18 - The Potential of CAR T Therapies 28:05 - The Allogeneic Space and Future Prospects 31:00 - The Transformative Impact of Cell Therapy 32:22 - Carlos's Career Lessons and Fear of the Unknown 34:45 - Closing Remarks and Subscription Reminder 36:37 - Outro---
When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024. Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patients also received intracranial injections of the checkpoint inhibitor combination: nivolumab + ipilimumab. At the conference, Oncology Times reporter Peter Goodwin caught up with lead author of the study, Bart Neyns, MD, PhD, Head of Medical Oncology at the Vrije Universiteit Brussel in the University Hospital Brussels Faculty of Medicine & Pharmacy in Belgium.
In this episode, Dr. Cremers discusses the differences between PRP and Autologous Serum Drops in treating Dry Eye Syndrome.
Ashley covers for Glenn as he heals from his recent procedure. She and Jamie have an exciting show for you, with Joy Hills of the Retired Racehorse Radio podcast joining us to recap the recent Retired Racehorse Makeover and Jenn is joined by Dr. Bobby Cowles, DVM, MS, MBA to educate us all on Autologous protein solution (APS) and how could it help horses with Synovitis. Listen in…HORSES IN THE MORNING Episode 3547 – Show Notes and Links:Guest: Joy Hills | Retired Racehorse RadioGuest: Dr. Bobby Cowles, DVM, MS, MBA, Managing Veterinarian, Equine Technical Services, ZoetisLink: Zoetis Equine Lameness solutionsLink: Zoetis Equine ProductsAdditional support for this podcast provided by: Daily Dose Equine, State Line Tack, RideTV, and Listeners Like YouTime Stamps:2:55 - Daily Whinnies 13:08 - Retired Racehorse Makeover Recap 24:55 - Horse Health Report with Dr. Bobby Cowles35:29 - Weird News
Ashley covers for Glenn as he heals from his recent procedure. She and Jamie have an exciting show for you, with Joy Hills of the Retired Racehorse Radio podcast joining us to recap the recent Retired Racehorse Makeover and Jenn is joined by Dr. Bobby Cowles, DVM, MS, MBA to educate us all on Autologous protein solution (APS) and how could it help horses with Synovitis. Listen in…HORSES IN THE MORNING Episode 3547 – Show Notes and Links:Guest: Joy Hills | Retired Racehorse RadioGuest: Dr. Bobby Cowles, DVM, MS, MBA, Managing Veterinarian, Equine Technical Services, ZoetisLink: Zoetis Equine Lameness solutionsLink: Zoetis Equine ProductsAdditional support for this podcast provided by: Daily Dose Equine, State Line Tack, RideTV, and Listeners Like You
GUEST: John Ronald, London (ON, Canada)Welcome back! It has been a while but are back with a bang, having our good friend John Ronald from The Robarts Research Institute in London, Ontario as our guest. John's group combines advances in molecular and synthetic biology with a multimodal imaging perspective to build new tools for early detection and treatment of cancer, as well as non-invasive monitoring of cell, gene and genome therapies. One of John's passions is gene reporter imaging, which is also the main focus of this edition. The paper up for discussion comes from Cynthia Dunbar's lab at NIH, Bethesda which was recently published in Cell Stem Cell. We discover their approach to non-invasively follow engraftment and maturation of pluripotent stem cells in rhesus macaques with myocardial infarctions, discuss some of the technicalities of engineering autologous cells, and fall in love with the beautiful RNAScope images that are presented. We discuss what makes a good imaging reporter, why one size doesn't always fit all, and a future where not just cells, but activation states can be imaged. Along the way, John also shares advices received from the wonderful Sanjiv Sam Gambhir on how to improve the chances of getting your grants funded and that supposedly crazy ideas should not be discarded... they might even lead to high impact publications.And of course, true to our tradition, we enjoy a special cocktail. For this edition the “Angry Canadian”, obviously. For the curious listeners: a good measure of Whisky, 2 tablespoons of fine Canadian Maple syrup, a few drops of bitters and 1 teaspoon lemon juice, then top up with soda water.Selected Publication: Lin Y, Sato N, Hong S, Nakamura K, Ferrante EA, Yu ZX, Chen MY, Nakamura DS, Yang X, Clevenger RR, Hunt TJ, Taylor JL, Jeffries KR, Keeran KJ, Neidig LE, Mehta A, Schwartzbeck R, Yu SJ, Kelly C, Navarengom K, Takeda K, Adler SS, Choyke PL, Zou J, Murry CE, Boehm M, Dunbar CE. Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques. Cell Stem Cell. 2024 Jul 5;31(7):974-988.e5. doi: 10.1016/j.stem.2024.05.005. Epub 2024 Jun 5. PMID: 38843830; PMCID: PMC11227404. https://www.cell.com/cell-stem-cell/abstract/S1934-5909(24)00182-6Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu
In the last episode, you heard Dr. Shah discuss autologous stem cell transplants. In today's episode, you'll meet Kim Rodning, the first non-trial recipient of an autologous stem cell transplant at Duke University. Like many scleroderma warriors, Kim remains positive and upbeat, even in the face of adversity. Her story is truly heartwarming.
Send us a Text Message.Dive into the cutting-edge world of autologous cell-based therapy with Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich. In this eye-opening episode, discover how MUVON Therapeutics' innovative approach to muscle regeneration is revolutionizing treatments for stress urinary incontinence and beyond.Learn how her team is tackling the challenges of bringing personalized medicine to market at scale, from navigating complex regulations to automating production processes.Listeners will gain invaluable insights on:Strategies for engaging with regulatory bodies to advance novel therapiesThe crucial role of automation in making cell therapies accessible and affordableBuilding successful partnerships to accelerate biotech innovationWhether you're a scientist, investor, or healthcare professional, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore how Deana's vision of "copy-paste" therapy production could transform millions of lives and reshape the biotech landscape!Connect with Deana Mohr:LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4MUVON Therapeutics: https://www.muvon-therapeutics.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com
Send us a Text Message.Discover how scientists are transforming lives through innovative muscle regeneration therapy. In this captivating episode, Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich, unveils her groundbreaking autologous muscle regeneration technology for treating stress urinary incontinence.Learn how this minimally invasive treatment harnesses the power of a patient's own cells to restore muscle function, offering hope to millions. Diana shares her journey from PhD research to clinical trials, revealing the challenges of translating cutting-edge science into real-world treatments.Listeners will gain insights on:The potential of autologous muscle tissue regeneration and the hurdles of medical innovation.Navigating the complex path from lab to clinicKey differences between muscle-based and CAR-T cell therapiesWhether you're a scientist, investor, or simply curious about medical innovations, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore the forefront of biotech entrepreneurship!Connect with Deana Mohr:LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4MUVON Therapeutics: https://www.muvon-therapeutics.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com
This edition of the DiepCJourney podcast highlights a recently published paper in JPRAS, an International Journal of Surgical Reconstruction. The title of the paper is: Flap neurotization improves sensation outcomes in abdominally based autologous breast reconstruction: A systematic review and meta-analysis. To our listeners, who may be patients, surgeons, or medical professionals we are going to explore the elements and details of this research paper and how it can be of benefit to you. I am pleased to have two returning guests who have collaborated across continents from Australia to the U.S. sharing their combined microsurgical skills to improve patient outcomes in sensate breasts. Dr. Joe Dusseldorp is an author of the paper and an internationally trained microsurgeon who practices in Sydney, Australia. He works alongside oncologists to perform innovative treatments for breast reconstruction, which includes DIEP flap. He is a TEDx speaker, a fellow of the Royal Australasian College of Surgeons, Australian Society of Plastic Surgeons, Faculty of Medicine at University of Sydney, and affiliated with the Chris O'Brien Lifehouse. My second guest, Dr. Minas Chrysopoulo, is the current president of PRMA, Plastic Reconstructive Microsurgical Associates, in San Antonio, Texas. Dr. C is a board-certified plastic surgeon, breast reconstruction surgeon and microsurgeon who like Dr. Joe, performs autologous based breast reconstruction. Raised and educated in London, England he has earned and received many academic achievements throughout his career. He continued his microsurgical training after moving to the U.S. and has authored and co-authored several book chapters and scientific articles in peer-reviewed journals. He is the developer of the award-winning free Breast Advocate® app that provides anyone with breast cancer a much-needed voice in their breast cancer surgery decision making. Connect with Dr. Joe Dusseldorp: LinkedIn: https://www.linkedin.com/in/joedusseldorp/ Instagram: https://www.instagram.com/drjoedusseldorp/ Facebook: https://www.facebook.com/joe.dusseldorp X: https://x.com/drjoedusseldorp Links to find the work of Dr. Minas Chrysopoulo: LinkedIn: https://www.linkedin.com/in/drchrysopoulo/ Instagram: https://www.instagram.com/mchrysopoulo/ Facebook: https://www.facebook.com/DrChrysopoulo X: https://x.com/drchrysopoulo
In this episode of the PRS Global Open Keynotes Podcast, Dr. Meredith Collins outlines 20 pearls to optimize the cosmetic outcomes of DIEP flap breast reconstruction. Plastic surgeons have now gone well beyond just being satisfied with a flap that is alive - cosmesis, symmetry and beauty are the new goals of treatment. This episode discusses the following PRS Global Open article: Optimizing Aesthetic Outcomes in Autologous Breast Reconstruction: 20 Pearls for Practice by Lauren M. Sinik, Audrey Le, Henrietta Ehirim and Meredith S. Collins. Read the article for free on PRSGlobalOpen.com: https://bit.ly/Aesthetic20 Dr. Meredith Collins is a board-certified plastic surgeon and associate professor at the University of Kansas. Your host, Dr. Damian Marucci, is a board-certified plastic surgeon and Associate Professor of Surgery at the University of Sydney in Australia. #PRSGlobalOpen #KeynotesPodcast #PlasticSurgery
Today, we have the pleasure of interviewing Flora Stondell, an advanced practice manager and assistant director at UC Davis Comprehensive Cancer Center. Flora's extensive experience in bone marrow transplants, particularly in malignant hematology, transplant, and cellular therapy provide us with invaluable insights.Flora begins by sharing her journey into the field, highlighting her accidental start in transplant care and her enduring passion for her patients. Her commitment is evident as she continues to balance her clinical work with her leadership role, always prioritizing patient care and workflow improvements.We then delved into the importance of screenings in early survivorship. Flora emphasizes that routine screenings, often neglected during the intense phases of treatment, need to be revisited post-transplant. These include mammograms, gynecologic exams, colonoscopies, dental care, and eye exams. These screenings are crucial to detect any preventable issues and address the heightened risk of certain cancers and other health concerns post-transplant.Vaccinations were another critical topic. Flora explains the different schedules for autologous and allogeneic stem cell transplant patients. Autologous patients typically start their vaccinations about six months post-transplant, while allogeneic patients' schedules depend on their immune system status and medication regimen. She stresses the importance of working closely with healthcare providers to ensure vaccinations are administered safely and effectively.We also cover Graft-Versus-Host Disease (GVHD), a common complication where donor cells attack the recipient's body. Flora describes the various manifestations of GVHD, with skin rashes being the most common and easier to treat, compared to gastrointestinal symptoms which are more challenging. She urges patients to report any symptoms promptly to their healthcare team to ensure early intervention and better outcomes.Flora provides reputable resources for further information on GVHD, including the GVHD Alliance, nbmtLINK, BMT Infonet, and the National Marrow Donor Program (NMDP). We also acknowledged the Meredith Cowden Foundation for its dedication to GVHD awareness and support.Caregiver support is another vital area discussed. Flora highlights the importance of acknowledging caregiver fatigue and ensuring caregivers seek support and communicate openly about their needs. She emphasizes the importance of caregivers taking care of their own health to provide better care for their loved ones.In wrapping up, Flora advises patients to be patient with their recovery process, recognizing that it can take months or even years to regain their strength. She also acknowledges the psychological impact of the transplant journey, mentioning that PTSD can occur even years later. Flora encourages patients to seek mental health support if needed.Flora's insights were not only informative but deeply compassionate, reflecting her dedication to improving the lives of transplant patients and their families. We are grateful for her expertise and the valuable information she shared.Resources:PDF files of vaccination Schedules for Auto and Allo TransplantsUC Davis Comprehensive Cancer Center : https://health.ucdavis.edu/cancer/GVHD Alliance: https://www.gvhdalliance.org/Meredith Cowden Foundation http://www.cowdenfoundation.org/BMT Infonet https://www.bmtinfonet.org/NMDP (National Marrow Donor Program) https://bethematch.org/National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to our sponsors. This season is supported by a healthcare contribution from Sanofi https://www.sanofi.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/
In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovations, and Techniques (JVS-CIT). Editorials and Abstracts are read by members of our SVS Social Media Ambassadors and Editor in Chief of JVS CIT, Dr. Matthew Smeds. Readers: Matthew Smeds (@mattsmeds) Christopher DeHaven (@ChrisDeHavenPSU) Ethan Vieira Litton Whittaker Nicholas Schaper Nishi Vootukuru (@Nishi_Vootukuru) Editorials: Accomplishments and goals: Review of 2023 and previous of 2024 for the Journal of Vascular Surgery Cases, Innovations, and Techniques. The enduring success of the DRIL technique and new advances in dialysis access. Abstracts: Intraprocedural application of a peripheral blood flow monitoring system during endovascular treatment for femoropopliteal disease. Thoracic outlet syndrome: single-center experience on the transaxillary approach with the aid of the TRIMANO Arthrex arm. Inferior vena cava hemangioma resected using a novel Toumai robotic surgical platform. Surgical release of anterior tibial artery entrapment with associated popliteal artery entrapment. Revisiting Heinz-Lippman disease as a complication of chronic venous insufficiency. Utilization of coronary computed tomography angiography and computed tomography-derived fractional flow reserve in a critical limb-threatening ischemia cohort. A rare case of Bannayan-Riley-Ruvalcaba syndrome with concurrent arteriovenous malformation. Autologous and synthetic pediatric iliofemoral reconstruction: A novel technique for pediatric iliofemoral artery reconstruction. Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.
Dr. John Sturges, a pioneer in regenerative medicine, discusses using the body's natural healing properties to treat injuries without drugs or surgery. He shares his journey into regenerative work with PRP and ACP, highlighting the evolution of stem cell research and its application in his clinic for over 15 years. The conversation delves into the intersection of regenerative medicine and musculoskeletal health, offering insights into innovative treatment approaches for sports injuries, repetitive use injuries, and chronic pain.Timestamps(02:27) Dr. Sturges discusses the importance of placing cells near the field of work for more efficacy in regenerative medicine.(10:36) Dr. Sturges shares his experience injecting his knee weekly for 30 weeks with regenerative injections, resulting in better healing compared to cortisone injections.(19:55) Dr. Sturges mentions the importance of applying pressure to promote healing in musculoskeletal tissues, highlighting the significance of specific techniques in regenerative medicine.(29:26) Dr. Sturges emphasizes the value of using musculoskeletal ultrasound for precise injections, leading to better outcomes in regenerative treatments.(42:39) Dr. Sturges discusses the potential for insurance companies to cover regenerative treatments, highlighting the need for proper training and infrastructure in the field.Host BioThis podcast is hosted by Sheree Dibiase, PT ICLM. She is a nationally recognized women's health physical therapist who owns seven private clinics — one of the biggest networks in the US. She has spent 30+ years practicing in the oncology, pelvic floor, and prenatal postpartum healthcare spaces. She was also a professor for seven years a Loma Linda University where she taught kinesiology. Brought to you by...https://lakecitypt.com/ - Women's health physical therapy. https://pelvicfloorpro.com/ - Pelvic floor physical therapy from home. KeywordsFemtech, Women's Health, Pelvic Floor, Breast Cancer, Prenatal & postpartum
In this episode of the Award-winning PRS Journal Club Podcast, 2024 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Amanda Sergesketter- and special guest Joseph Serletti, MD, discuss the following articles from the March 2024 issue: “Relationship between Body Mass Index and Outcomes in Microvascular Abdominally Based Autologous Breast Reconstruction” by Barnes, Lem, Patterson, et al. Read the article for FREE: https://bit.ly/BMIBreastRecon Special guest Dr. Joseph Serletti has completed his residency training at the University of Rochester followed by a craniofacial fellowship at Johns Hopkins under Dr. Paul Manson. He then practiced at and became Chief of Plastic Surgery at the University of Rochester before moving to Philadelphia where he has been the Henry Royster-William Maul Measey Professor in Plastic Surgery and Chief of Penn Plastic Surgery. He has been a leader in microsurgery and is past president of the American Society for Reconstructive Microsurgery as well as current Secretary for the American Association of Plastic Surgeons. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMarch24Collection
In this episode of the Award-winning PRS Journal Club Podcast, 2024 Resident Ambassadors to the PRS Editorial Board – Rami Kantar, Yoshi Toyoda, and Amanda Sergesketter- and special guest Joseph Serletti, MD, discuss the following articles from the March 2024 issue: “Relationship between Body Mass Index and Outcomes in Microvascular Abdominally Based Autologous Breast Reconstruction” by Barnes, Lem, Patterson, et al. “Developing a Craniofacial Soft-Tissue Anthropomorphic Database with Magnetic Resonance Imaging and Unbiased Diffeomorphic Registration” by Villavisanis, Khandelwal, Zapatero, et al. “Financial Literacy in Plastic Surgery Training: Importance and Current Status” Krasniak, Kraft, O'Brien, et al. Special guest Dr. Joseph Serletti has completed his residency training at the University of Rochester followed by a craniofacial fellowship at Johns Hopkins under Dr. Paul Manson. He then practiced at and became Chief of Plastic Surgery at the University of Rochester before moving to Philadelphia where he has been the Henry Royster-William Maul Measey Professor in Plastic Surgery and Chief of Penn Plastic Surgery. He has been a leader in microsurgery and is past president of the American Society for Reconstructive Microsurgery as well as current Secretary for the American Association of Plastic Surgeons. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMarch24Collection #PRSJournalClub
In this episode of Biohacking Superhuman Performance with guest Dr. Amy Killen, we explore the world of stem cells - what they are, how they perform in the body, and how they work to increase longevity. Stem cell therapy is still being researched and regulated, but there is an amazing amount of potential for healing and increasing longevity with these powerful cells. We also dive into exosomes - the small molecules that can penetrate places that stem cells can't. Aesthetic procedures are popular with exosomes- they have the power to restore hair and rejuvenate skin, and are used in many skincare products. We even go over ovarian rejuvenation and Rapamycin, a potential prescription drug for delaying menopause. Overall, this episode offers guidance on stimulating stem cells right in your own home. We talk through different tips such as supplements, fasting, and getting sun in a healthy way for those who aren't in a place to budget for stem cell therapy. Dr. Amy Killen is an outspoken advocate for empowering people to look and feel their best by merging lifestyle modification, integrative medicine, body-identical hormones, energy modalities, and stem cell therapies. She is the founder and CEO of the Human Optimization Project (HOP), a longevity-based subscription supplement company that stays on top of the science and constantly updates its ingredients for customers who can't devote their lives to reading the latest research sourcing the best therapies. I absolutely love her Instagram. You guys need to go follow her @dr.amybkillen. Get Rapid Rebound oral BPC157 with PEA and AOD9604. Visit https://lelabs.co/ and use code NAT20 Thank you to our sponsors for making this episode possible: Sensate: Use code NAT at www.getsensate.com/Nat BEAM Minerals: Go to https://www.beamminerals.com code Nathalie to get 20% off your order Profound Health: Use code longevity15 to save 15% off your first order at https://profound-health.com/ Find more from Dr. Amy B. Killen: Website: https://dramykillen.com/ Youtube: https://www.youtube.com/channel/UCBLk8xTa4qzE7J8bID7KIKg Instagram: @dr.amybkillen Human Optimization Project (HOP box): https://hopbox.life/ Find more from Nathalie: YouTube: https://www.youtube.com/channel/UCmholC48MqRC50UffIZOMOQ Facebook Group: https://www.facebook.com/groups/biohackingsuperhumanperformance Instagram: https://www.instagram.com/nathalieniddam/ Website: https://www.NatNiddam.com Join Nat's Membership Community: https://www.natniddam.com/bsp-community Work with Nat: Book Your 20 Minute Optimization Consult: https://calendly.com/nniddam/intro-call?month=2021-08 What We Discuss: (1:30) Women's unfounded fear around Hormone Replacement Therapy (5:38) When you start hormones early you reduce the risk of major women-killing diseases such as heart disease and obesity. (7:20) The world of stem cells and exosomes- what they are, and why they are important. (11:20) MSC cells are very safe, don't cause cancer, and they're not embryonic cells (no fetus is harmed!) (13:50) The Pros of using birth product stem cells (from the placenta and umbilical cord) (18:08) The environment where the stem cells are placed matters. (22:50) Helpful therapies to stack with stem cell therapy. (30:50) What the research shows about stem cell therapy and diseases like MS. (34:15) Exosomes - one of the signaling molecules of stem cells. i (41:37) Fat transfers are a great natural filler, but adding stem cells creates better results. (44:50) How to stimulate stem cells naturally if you don't have the budget for stem cell therapy. (58:30) The overuse of supplements and HOP box. (1:04:00) Rapamycin and ovarian rejuvenation using stem cells. (1:10:38) Where to find more from Dr. Amy B Killen. Key Takeaways: 1. Stem cells do two main things. They can replicate themselves and they can turn into other types of cells. Stem cells send out signals so that an injured area heals itself. When we age, we have fewer, less active stem cells. They aren't able to signal repair as well, so recovery takes much longer. Stem cell therapy gives you back signaling molecules so that you're able to heal yourself faster. Autologous stem cells are your own cells from fat tissue or bone marrow. Allogeneic stem cells come from somewhere else - like birth tissue products (placenta/umbilical cord). The environment affects the stem cells. The area where you put stem cells matters, and if your body is not healthy, is inflamed, or has uncontrolled blood sugar issues, the cells cannot work as well. For example: a smoker or poorly controlled diabetic won't have the best results. Take the time to get in the best shape that you can before a costly procedure like stem cell therapy. Exosomes are powerful signaling molecules that can be transported into cells to change the behavior of that cell. These small molecules can pass through the skin- they can be applied topically - and they can cross the blood brain barrier to decrease inflammation. They're great for aesthetic purposes like hair restoration and skin rejuvenation. The FDA regulates the application - they can only be applied topically. Bonus takeaway: No drug can do what hormones do when used properly at the right time in the right way. If you want to be healthy for longer, especially after menopause, you need to be looking into HRT.
“There's still so much we need to learn.” Dr João Marcelino joins Professor Marcus Maurer to discuss autoimmune chronic spontaneous urticaria, including indicative test results and hopes for the future. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Utilise the following external links and access additional resources relating to the topics discussed in this episode: What basophil testing tells us about CSU patients – results of the CORSA study, Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions and Omalizumab in chronic spontaneous and inducible urticaria: A 9-year retrospective study in Portugal. Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.
BUFFALO, NY- January 9, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 24, entitled, “Systemic changes induced by autologous stem cell ovarian transplant in plasma proteome of women with impaired ovarian reserves.” Patients with poor ovarian response (POR) and premature ovarian insufficiency (POI) are challenging to treat, with oocyte donation remaining as the only feasible option to achieve pregnancy in some cases. The Autologous stem cell ovarian transplantation (ASCOT) technique allows follicle development, enabling pregnancies and births of healthy babies in these patients. Previous research suggests that growth factors and cytokines secreted by stem cells are partially responsible for their regenerative properties. Indeed, ASCOT beneficial effects are associated with the presence of different bone marrow derived stem cell- secreted factors in plasma. In this new study, researchers Anna Buigues, Noelia Ramírez-Martin, Jessica Martínez, Nuria Pellicer, Marcos Meseguer, Antonio Pellicer, and Sonia Herraiz from IVIRMA Global Research Alliance aimed to assess whether ASCOT induces any modifications in the plasma proteomic profile of patients with impaired ovarian reserves. “In this study, we aimed to assess if the ASCOT technique modifies the signature of the human plasma proteome, reveal the mechanisms underlying its beneficial effects on the ovary, and identify key regulators of ovarian aging.” Discriminant analysis highlighted clear distinctions between the plasma proteome before (PRE), during stem cell mobilization and collection (APHERESIS) and three months after ASCOT (POST) in patients with POR and POI. Both the stem cell mobilization and ASCOT technique induced statistically significant modifications in the plasma composition, reversing some age-related protein expression changes. In the POR group, functional analysis revealed an enrichment in processes related to the complement cascade, immune system, and platelet degranulation, while in the POI group, enriched processes were also associated with responses to oxygen-containing compounds and growth hormones, and blood vessel maturation. “In conclusion, our findings highlight the potential proteins and biological processes that may promote the follicle activation and growth observed after ASCOT.” DOI - https://doi.org/10.18632/aging.205400 Corresponding author - Sonia Herraiz - sonia_herraiz@iislafe.es Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205400 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, plasma proteomic profile, autologous stem cell ovarian transplantation, poor ovarian response, premature ovarian insufficiency About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM
Dr. James Chao, MD, FACS is a board-certified plastic surgeon, reconstructive surgeon, and microsurgeon, who has performed thousands of reconstructive breast surgeries. A staunch proponent for the furtherance of Women's Sexual Health, Dr. Chao trained at Stanford University, NYU Medical School, and is a Professor Emeritus of Plastic Surgery at UC San Diego. Dr. Chao is the CEO of Prime Plastic Surgery, Prime Med Spa, and FEM MD. He makes an appearance alongside @drdubrow + @drpaulnassif on @botchedtv in a complex case this season. As a fellowship-trained hand and microvascular surgeon who specializes in cosmetic and reconstructive surgery, Dr. Chao is something of a polymath, to say the least, with specialties in aesthetic and reconstructive breast surgery, women's sexual health surgery + the development of new technologies in the field of plastic surgery. Dr. Chao wants women to know that we are not alone and we have options when it comes to breast reconstruction after breast cancer. Here is what we talk about on this show: The pros and cons of Autologous vs. Prosthetic surgery: AKA using your own tissue vs. getting breast implants. We discuss the microsurgical techniques that are involved in autologous reconstruction, and how important it is to pick the right surgeon with any option you choose. We talk about the TRAM flap surgery vs. the newer DIEP flap surgery, how these procedures are done, where the tissue is taken from, and who is a candidate for them. We also talk about going flat which is choosing not to reconstruct a breast at all. We get into whether to reconstruct both breasts if only one is affected, tissue expanders, a 1 part surgery vs a 2 part surgery. We discuss the more common prosthetic route, which is using implants to reconstruct the breast, the pros and cons, the types of implants, and cutting-edge digital surgery available to assist in making the choice that is best for you. We talk about the importance of choosing a team you have confidence in including the surgeon who removes breast cancer, the medical oncologist, and the surgeon who reconstructs the breast(s). We talk about resources for looking into board certification and how necessary it is to like your surgeon. When facing cancer, women are thinking more about surviving the disease instead of how their breasts going to look after the fact. However, this is important to our sexual health and overall quality of life. One out of every 8 American women will get the diagnosis, but there is over 95% chance that you will survive it if it's caught early, so get your mammogram! For checking board certification: The American Board of Plastic Surgery https://www.abplasticsurgery.org/ American Society of Plastic Surgeons https://www.plasticsurgery.org/ Support Groups: American Cancer Society https://donate.cancer.org/ For more on Dr. Chao: http://primeplasticsurgery.com and http://oasismd.com Disclaimer: CLITEROLOGY is for general information and entertainment purposes only and does not constitute the practice of medicine in any way. CLITEROLOGY does not constitute professional health care services or medical advice. No doctor/patient relationship is formed as a result of this podcast. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of CLITEROLOGY is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard getting medical advice for any such medical condition they may have and should seek the assistance of their healthcare professionals for any conditions.
In this week's episode, we pause from our discussion about DLBCL to talk about the fundamentals of CAR-T, BiTE and autologous transplants, which will lay the foundation for subsequent discussions about DLBCL. These therapies are the talk of the town and have changed/will continue to change our approach to hematologic malignancies - definitely an episode you don't want to miss. Content: - What is CAR-T?- How are CAR-T cells manufactured?- What are commercially available CAR-T cell products? - What are side effects of CAR-T? - What is BiTE therapy?- What is the role of autologous transplants in lymphoma? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
Autologous cell treatments are already making an impact in our lives today but the truth is we are only just scratching the surface of what might be possible. In our lifetime, aesthetic regenerative medicine will make a dramatic leap forward. The problem is that as our cells age they become less potent. That means many of us will never be able to experience the full impact of emerging regenerative innovation. On episode no. 85 of the Technology of Beauty we hear from the CEO of a startup that has not only set out to solve this problem, but already has a solution in the marketplace designed to prepare today's generation for the regenerative advances ahead. Meet Acorn Biolabs — The first non-invasive solution to preserve your younger follicle cells for use in regenerative medicine.From locking in cell age with cryogenic preservation to developing a process for autologous cell regeneration that could speculatively allow for 3D-printing a pancreas, Acorn CEO Drew Taylor describes it all so clearly that it feels less like science fiction, and more like inevitable future fact.But if it still seems too far off, or too good to be true, the first applications for these autologous cell-based therapies lie squarely in the realm of aesthetic medicine, where they are currently testing applications for their first cell-derived product composed of iPSCs — induced pluripotent stem cells.Find out what it all means and stick around for a demonstration of the harvesting procedure on Dr. Grant Stevens himself on the latest episode of The Technology of Beauty.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/
In this episode of Evaluating Biopharma, host Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Jonathan Tsang, Senior Director, Manufacturing Sciences & Technology at Kite Pharma, who shares his experiences and provides advice on how autologous cell therapy companies can better prepare for commercial manufacturing, including: addressing the challenge of variability of patient cell behavior, process development characterization using healthy donor vs. patient cells, volume and logistical complexity of personalized therapy, and planning and implementing fast and efficient business systems to support scale-out. He also discusses critical quality attributes he looks for during process development and his thoughts on developing processes that can cope with variability in reagents, media, and more. Links from this episode: Evaluating Biopharma Black Diamond Networks Kite Pharma Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today's decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.
Emily Foreman, CCP reviews her peer-reviewed publication on RAPP as a transfusion management procedure. In this YouTube video, Emily Foreman, CCP presents the findings of a paper published towards the end of 2021. The paper is titled "To Wrap or Not to Wrap." The purpose of the study was a quality improvement project to determine if wrapping during cardiac surgeries was beneficial for their patients. The speaker explains that their institution has a low prime bypass circuit and a strict anesthesia preoperative protocol. They analyzed about 40 different data points on each patient and examined reported benefits and possible negative consequences of wrapping during cardiac surgeries. They conducted a retrospective study by comparing two groups of patients: those who were wrapped during surgery and those who were not. They looked at various factors, including red blood cell transfusion index, oxygen delivery, postoperative acute kidney injury, albumin administration, ventilator times, ICU length of stay, and 30-day mortality. The speaker presents their original theories, such as the belief that wrapping may negatively impact acute kidney injury incidence and reduce oxygen delivery. However, their analysis revealed that wrapping did not have a statistically significant impact on most of the studied parameters. The only notable finding was a higher post-operative albumin administration in the wrapped group. The conclusion drawn from the study was that wrapping during cardiac surgeries was not beneficial in their patient population, considering their specific preoperative fluid administration protocols and prime circuit. They also mention the need for further research, particularly in cases involving condensed circuits. Overall, the study did not support the idea that wrapping was advantageous for their patients, and the speaker highlights the limitations and challenges they faced during the analysis.
In this episode, host Dr. Jacob Fleming interviews Dr. Edward Yoon, interventional MSK radiologist and Chief of IR at the Hospital for Special Surgery. The doctors discuss novel intradiscal therapies to treat anterior column pain, as well as where the field of spine interventions is heading. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/teT47L --- SHOW NOTES Dr. Yoon outlines his path to his current specialty area. His interest in orthopedics and minimally invasive techniques led him to pursue fellowships in MSK radiology and spine intervention. He highlights how MSK IR is emerging as a cousin to orthopedic surgery, in the same way that VIR is related to vascular surgery. With nine different specialties practicing interventional pain and spine procedures, Dr. Yoon believes that IRs can differentiate themselves by taking ownership of follow up care and complications management. He emphasizes the importance of building a practice instead of waiting for patients to be referred to you. He also highlights the need to collaborate with colleagues in different specialties (orthopedics, PMR, pain management) to educate them about novel IR techniques and patient populations that could benefit from these. Next, the doctors discuss the leading cause of low axial chronic back pain: stable discogenic pain. Though there has not been a proven treatment to halt degenerative disc disease, there are a few therapies that could help patients with painful symptoms. Dr. Yoon describes his use of anesthetic discogram as a diagnostic and therapeutic tool for discogenic back pain. His injectant is a mix of lidocaine and dexamethasone, and he observes if the patient experiences pain relief. Due to literature that links discograms with accelerated disc degeneration, discograms are less commonly performed today. However, Dr. Yoon believes that many younger patients already have degenerated discs when they present for evaluation and every interventional procedure poses some risk that can reasonably be evaluated in collaboration with the patient. Alongside imaging, he evaluates patient symptoms, the most common being midline back pain that gets worse with flexion or axial loading. Dr. Yoon also offers tips for reading spine MRIs, which include adopting a systematic approach, noting important incidental findings, and correlating findings with patient symptoms. Finally, Dr. Yoon highlights some exciting therapies that are currently under investigation. The VIA Disc procedure involves an allographic injection of ground up nucleus pulposus into the disc. From the VAST Trial, there is data showing that treatment responders experience pain reduction and improved functioning. Autologous injection options include platelet rich plasma (PRP) and bone marrow aspirate concentrate (BMAC). Spinal modic changes could be treated with basivertebral nerve ablation (BVNA), which is a good option that is low-risk and does not preclude the possibility of future interventions. All of these therapies come with the caveat of unreliable insurance coverage, since many private payers are hesitant about approving them. The disconnect between evidence-based therapies, patient needs, and insurance coverage needs to be addressed if these therapies are to become mainstream. --- RESOURCES VAST Clinical Trial: https://pubmed.ncbi.nlm.nih.gov/34554689/ VIA Disc NP: https://gotviadisc.com/ Owestry Disability Index (ODI): https://www.aaos.org/quality/research-resources/patient-reported-outcome-measures/spine/ SMART Trial: https://pubmed.ncbi.nlm.nih.gov/32451777/ INTRACEPT Trial: https://www.nassopenaccess.org/article/S2666-5484(21)00041-X/fulltext
Indications for use of intraoperative autologous red blood cell salvage by AORNJournal
Contraindications for use of intraoperative autologous red blood cell salvage by AORNJournal
In this podcast, we talked with Dr. Ma Sha, Head of Bioprocess Applications at Eppendorf SE about advancements and challenges in cell and gene therapy production along with solutions for scale up and transition to stirred-tank bioreactor suspension culture. We began the interview by talking about the biggest advancements in cell and gene therapy, including CAR T-cell therapy development, clinical results and FDA approvals. Another area of great advancement is induced Pluripotent Stem Cell (iPSC) Culture technique. Dr. Sha explained that it used to be very difficult to culture iPSCs until it was possible to culture iPSC suspension spheres in stirred-tank bioreactors, which was a big breakthrough in the cell and gene therapy area. I followed up by asking Dr. Sha what he sees as the major challenges in the development and production of cell and gene therapies that still need to be addressed. He said that one of the major breakthroughs has been the autologous therapies that have been approved, particularly CAR T-cell therapies. However, this has also been a major challenge, because the autologous model is not cost effective. As a result, there has been a shift toward developing allogeneic therapies and building this production model will be a major challenge moving forward. Another challenge on the manufacturing side is ensuring to follow Good Manufacturing Practice (GMP), as it has been a common request from cell and gene therapy companies. Next, I asked him about the move from 2D to 3D culture and his experiences with this transition. Dr. Sha shared that several of the projects that Eppendorf bioprocess works on start as 2D culture in flasks, it is a natural place to start for most of the cell lines since they are attachment cells. They must then be converted into suspension culture to enable 3D culture, since 2D culture significantly limits the yield and productivity. He went on to say that if you look back at the evolution of antibody production, it was important to convert production to suspension cell culture and this is also necessary for the cell and gene therapy field. Moving from 2D to 3D culture and especially utilizing stirred-tank bioreactors enables much higher yields. As it stands, the yield for cellular therapy cell production is fairly low, especially compared to the industry standard of CHO cells used for antibody production, so a lot of improvement needs to happen. We then discussed stirred-tank bioreactors and their increased use in cell and gene therapy development and production. I asked Dr. Sha what are the key factors that developers should consider when choosing stirred-tank bioreactors. He explained that stirred-tank bioreactors fit the model of allogeneic production. Autologous models are not suitable for stirred-tank bioreactors. Developer companies need to keep in mind that if they want to move to stirred tank bioreactor platform, they need the production model to be allogeneic. In addition, it is important to consider the support available with respect to scaling up and leveraging supplier experience. For example, Eppendorf bioprocess over the years has produced many application notes to help customers scale their manufacturing. They have even built model production systems in Eppendorf stirred-tank bioreactors. The program called “Scale up Assist” allows customers to skip much of the difficult calculations required to achieve reproducible yields when moving from smaller to larger vessels. Eppendorf has a very long history of working in protein-based therapeutic cell culture production and about ten years ago expanded to include cell and gene therapy. I asked Dr. Sha in his experiences, what are the most important takeaways in terms of areas that still need work and advancements on the horizon. For instance, what can we learn from protein-based therapy cell culture to apply to cell and gene therapy production? He said that he thought that allogeneic production is a great lesson learn...
From novel treatments for hair loss and microinflammation to fat grafting and breast reconstruction, something transformative is unfolding at Bimini Health Tech, and CEO Brad Conlan is here to tell us about it. Standing squarely at the vanguard of autologous innovation — using an individual's own cells in the name of regenerative aesthetics — Bimini seeks to marry convenience and performance with technologies that stand to reshape the way we think about aesthetic treatments.With decades of experience in regenerative medicine, Brad offers an insider's look at everything from exosomes to stem cells and stromal vascular fraction. Tune in to find out how Bimini is unlocking the regenerative power of the human body with autologous, personalized medicine and what the future holds for this exciting segment of the aesthetic market.Show notes:0:00 Intro0:40 Aesthetics Innovation Summit1:31 Background3:58 Bimini origins6:52 A symphony of healing10:09 Current understanding of hair loss12:30 Aesthetics as a pipeline for products that work16:58 Fat grafting and breast reconstruction19:39 Anticipated raise22:57 Marrying convenience and performance 24:54 Other technologies Bimini is looking at29:07 Crystal ball» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/
Dr. Tina Albertson is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to find ways to counter the exhaustion that the T cells exhibit so that T cells can stay functional and kill the solid tumor cells. Tina explains, "Our cell therapies are from the patient's own cells, so these are what we call autologous cell therapies. We take the cells from the patient and bring them, in our case to Seattle, to our manufacturing facility. We both genetically and epigenetically reprogram them during manufacturing so that the cells will be resistant to the suppressive microenvironment of the solid tumors." " I think most people are familiar with the concept of stem cells, which can self-renew as well as make cells that are functional and can differentiate. So when we reprogram them, we make them more stem-like, and this allows us to infuse cells into the patient that should be more persistent and more functional." "The second product we're also testing in trials is tumor infiltrating lymphocytes or TILs. This is a product where you need a piece of their cancer or their tumor and extract the T cells from the tumor itself. That requires surgery, then a piece of tissue is also sent to our manufacturing facility. Those T cells are extracted and expanded. That takes a little bit longer. But similarly, once those are expanded to the right cell number, we send them back to the site to be reinfused into the patient." #Lyell #CellTherapy #SolidTumors #Oncology #Cancer #TCells #TCellExhaustion #AutologousCellTherapy lyell.com Download the transcript here
Dr. Tina Albertson is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to find ways to counter the exhaustion that the T cells exhibit so that T cells can stay functional and kill the solid tumor cells. Tina explains, "Our cell therapies are from the patient's own cells, so these are what we call autologous cell therapies. We take the cells from the patient and bring them, in our case to Seattle, to our manufacturing facility. We both genetically and epigenetically reprogram them during manufacturing so that the cells will be resistant to the suppressive microenvironment of the solid tumors." " I think most people are familiar with the concept of stem cells, which can self-renew as well as make cells that are functional and can differentiate. So when we reprogram them, we make them more stem-like, and this allows us to infuse cells into the patient that should be more persistent and more functional." "The second product we're also testing in trials is tumor infiltrating lymphocytes or TILs. This is a product where you need a piece of their cancer or their tumor and extract the T cells from the tumor itself. That requires surgery, then a piece of tissue is also sent to our manufacturing facility. Those T cells are extracted and expanded. That takes a little bit longer. But similarly, once those are expanded to the right cell number, we send them back to the site to be reinfused into the patient." #Lyell #CellTherapy #SolidTumors #Oncology #Cancer #TCells #TCellExhaustion #AutologousCellTherapy lyell.com Listen to the podcast here
Interview with Andrzej A. Piatkowski, MD, PhD, author of Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial. Hosted by Amalia Cochran, MD. Related Content: Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer
In this continuation of our myeloma series, we discuss all the key principles and data surrounding autologous stem cell transplant in myeloma. We provide a succinct summary of key trials in this space that will give you a deep understanding of the field. Content:- What are all these cooperative groups in the studies?- What are some of the important trials that show us the benefit of autologous stem cell transplant? - Should transplant be done early or should it be delayed? What does it matter? - We translate the data/guidelines into what this means for patients in real-life- How do we approach transplant in high risk patients in myeloma and what are the guidelines about tandem transplant? This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co.Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
In this special edition of the Award-winning PRS Journal Club Podcast, Dr. Summer E. Hanson discusses a prospective, randomized comparison of different autologous fat graft processing techniques. The episode was recorded LIVE at PSTM 2022 in Boston, Massachusetts with a live audience. Moderated by 2022 PRS Resident Ambassadors Said Azoury, MD, Emily Long, MD, and Ronnie Shammas, MD. READ the articles discussed in this podcast as well as free related content from the archives: https://bit.ly/PRSJC_LivePSTM22 #PRSJournalClub
In this special edition of the Award-winning PRS Journal Club Podcast, Dr. Summer E. Hanson discusses a prospective, randomized comparison of different autologous fat graft processing techniques. The episode was recorded LIVE at PSTM 2022 in Boston, Massachusetts with a live audience. Moderated by 2022 PRS Resident Ambassadors Said Azoury, MD, Emily Long, MD, and Ronnie Shammas, MD. READ the articles discussed in this podcast as well as free related content from the archives: https://bit.ly/PRSJC_LivePSTM22 #PRSJournalClub
Today, we're talking about a topic that you've told me is the topic that you'd most like me to cover on this podcast -- autologous hematopoietic stem cell transplantation, or HSCT. And I'm dedicating this entire episode of RealTalk MS to a deep dive on the subject with the man who pioneered autologous HSCT as a treatment for relapsing-remitting MS, Dr. Richard Burt. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Autologous HSCT with Dr. Richard Burt :23 Dr. Richard Burt takes us on a deep dive into autologous HSCT for MS :57 Share this episode 54:38 Have you downloaded the free RealTalk MS app? 54:59 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/281 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Amazon: Everyday Miracles: Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant by Dr. Richard Burt https://www.amazon.com/Everyday-Miracles-Scleroderma-Autoimmune-Hematopoietic/dp/B0BRNTJZ9X/ref=sr_1_1 National MS Society: aHSCT in MS https://nationalmssociety.org/Treating-MS/aHSCT Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 281 Guest: Dr. Richard Burt Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy
Mayo Clinic performed its first bone marrow transplant in 1963 and today hundreds of people receive blood and marrow transplants every year at Mayo Clinic in Arizona, Florida and Minnesota. Recently, Mayo Clinic in Rochester, Minnesota celebrated its 10,000th blood and marrow transplant.Bone marrow transplant is used to treat blood cancers and related disorders by infusing healthy blood-forming stem cells into your body to replace unhealthy bone marrow. A bone marrow transplant is also called a stem cell transplant. Bone marrow transplants may use cells from your own body, called autologous transplant, or from a donor, known as allogeneic transplant. Autologous stem cell transplants are typically used in people who are producing enough bone marrow but need to undergo high doses of chemotherapy and radiation to cure their disease. These treatments are likely to damage the bone marrow. Prior to treatment, healthy bone marrow cells are collected, frozen and stored for later use. After treatment, the stem cells are infused back into the patient to repopulate the bone marrow.Allogeneic bone marrow transplant is used when there is underlying bone marrow failure syndrome or for certain types of bone cancers and blood cancers. In those cases, donor bone marrow is needed to replace the diseased bone marrow.One common complication of allogenic transplant is developing graft versus host disease. This condition occurs when the donor stem cells see the body's tissues and organs as something foreign and attack them. Researchers have now discovered metabolic markers that can predict a person's risk for developing severe graft versus host disease, allowing for a more personalized treatment approach."Graft versus host disease occurs in patients that have had an allogeneic transplant from a donor," explains Dr. William Hogan, director of the Mayo Clinic Blood and Bone Marrow Transplant Program in Minnesota. "And this is where the donor immune system doesn't just recognize the leukemia that we're trying to treat — which is what we want — but it also attacks the patient's normal tissues. This can be anything from a relatively mild to a very devastating problem that can occur after transplant. And one of the challenges was that, by the time that has been fully developed, then it's harder to treat. So one of the goals of research in the last few years has been to develop markers that will tell us which patients are at risk of having the most severe graft versus host disease, and allowing us to target more effective treatment toward those patients."Other recent advances in blood and bone marrow transplant include the use of mismatched donors and the ability to use bone marrow transplant in older, more frail patients thanks to improvements in antibiotics, antifungal drugs and other medications.Another cellular therapy that is helping treat blood disorders and cancers is chimeric antigen receptor-T cell (CAR-T) therapy. CAR-T involves taking the T cells from a person and reengineering them to recognize and destroy cancer cells."CAR-T therapy is a very interesting therapy," says Dr. Hogan. "It's really come to fruition in the last five to 10 years. This is similar to bone marrow transplant, but not quite the same. It's a cellular-based therapy, so not a drug, but using cells that are modified in order to try and treat leukemias and other cancers. And basically, what it does is it takes our native immune system — and then the T cells specifically — and modifies them so that they are much more effective at recognizing targets that are on leukemia cells or other malignant cells. And that really kind of allows us to use the native immune system in a much more effective way of trying to kill leukemias." Dr. Hogan says CAR-T therapy also is being developed for noncancerous conditions, like aplastic anemia, and research is looking at CAR-T as a treatment for a particular form of inflammatory multiple sclerosis. "Things have really been transformed over the last five to 10 years with the advent of CAR-T therapy which has been groundbreaking," says Dr. Hogan. "The field of blood and bone marrow transplant continues to move forward, creating more effective treatments with less toxicity for many patients." On the Mayo Clinic Q&A podcast, Dr. Hogan discusses advances in bone marrow transplant and cellular therapy, including CAR-T.
In this episode of the Award-winning PRS Journal Club Podcast, 2022 Resident Ambassadors to the PRS Editorial Board – Saïd Azoury, Emily Long, and Ronnie Shammas- and special guest Bernard T. Lee, MD, MPH, discuss the following articles from the October 2022 issue: “The Palpable Nodule after Autologous Fat Grafting: Distinguishing Benign versus Malignant Lesions in Breast Reconstruction” by Fracol, Allison, Chu, et al. Read the article for FREE: https://bit.ly/NodulesFatGrafting Special guest Bernard T. Lee, MD, MPH, is currently the Chief of Plastic Surgery at Beth Israel Deaconess Medical Center, Editor-in-Chief of the Journal of Reconstructive Microsurgery, and current President of the Plastic Surgery Foundation (PSF). READ the articles discussed in this podcast as well as free related content from the archives: https://bit.ly/PRSOct22Collection
Commentary by Dr. Valentin Fuster
© 2020-2025 Ivy Podcast Discovery LLC
